Overview

• Study analyzed data from over 110,000 type 2 diabetics aged 40-69.
• SGLT-2 inhibitors linked to lower risk of Alzheimer's and vascular dementia.
• Experts call for robust clinical trials to validate results.
• Repurposing existing drugs could accelerate and reduce costs of dementia treatment.
• Researchers emphasize the need to understand the mechanisms behind the observed effects.